skip to main content

MDS suitability of MR formulations — GPhC CRA MCQ

Instant feedback + full explanation. One question, done properly.

ModerateDispensingMDS suitability of MR formulationsGPhC CRA

A pharmacist is preparing a monitored dosage system (MDS) for a care home patient. One of the medications is modified-release nifedipine 30 mg tablets. The care home has requested that all medications be placed in the MDS. What is the most appropriate action?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Do not place nifedipine MR tablets in the MDS as stability may be affected, and supply them separately in their original packaging

Modified-release formulations may not be suitable for inclusion in monitored dosage systems as stability data outside the original packaging may not be available. Removing MR tablets from their original packaging and placing them in an MDS could affect their stability and modified-release properties. The BNF and RPSGB guidance recommend that such formulations are supplied in their original packaging with clear labelling. The care home should be informed of this requirement.

Reference: MEP; RPSGB Guidance on MDS